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Abstract Evolutionary theories are critical for understand-
ing cancer development at the level of species as well as at
the level of cells and tissues, and for developing effective
therapies. Animals have evolved potent tumor-suppressive
mechanisms to prevent cancer development. These
mechanisms were initially necessary for the evolution
of multi-cellular organisms and became even more
important as animals evolved large bodies and long
lives. Indeed, the development and architecture of our
tissues were evolutionarily constrained by the need to
limit cancer. Cancer development within an individual is
also an evolutionary process, which in many respects
mirrors species evolution. Species evolve by mutation
and selection acting on individuals in a population;
tumors evolve by mutation and selection acting on cells
in a tissue. The processes of mutation and selection are
integral to the evolution of cancer at every step of
multistage carcinogenesis, from tumor genesis to metastasis.
Factors associated with cancer development, such as aging
and carcinogens, have been shown to promote cancer
evolution by impacting bothmutation and selection processes.
While there are therapies that can decimate a cancer cell
population, unfortunately cancers can also evolve resistance to
these therapies, leading to the resurgence of treatment-
refractory disease. Understanding cancer from an evolutionary
perspective can allow us to appreciate better why cancers
predominantly occur in the elderly and why other conditions,
from radiation exposure to smoking, are associated with
increased cancers. Importantly, the application of evolutionary
theory to cancer should engender new treatment strategies that
could better control this dreaded disease.
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Why Understanding Cancer from an Evolutionary
Perspective is Important
We expect that the public generally views evolutionary
biology as a science about the past, with stodgy old professors
examining dusty fossils in poorly lit museum basements.
Evolution must certainly be a field well separated from
modern medicine and biomedical research, right? If the public
makes a connection between evolution and medicine, it is
typically in the example of bacteria acquiring antibiotic
resistance. But what does evolution have to do with afflictions
like heart disease, obesity, and cancer? As it turns out, these
diseases are intricately tied to our evolutionary histories, and
understanding evolution is essential for preventing, managing,
and treating these diseases (Greaves 2007; Nesse 2001). This
review will focus on cancer: how evolutionary theories can
be used to understand cancer development at the level of
species as well as at the level of cells and tissues. We will
also discuss the implications and benefits of an evolutionary
perspective toward cancer prevention and therapies.
Life History, Lifespan, and Cancer
For almost all animals, old age is associated with a general
decline in tissue structure and function. This decline is thought
to reflect the lack of selective pressure to maintain tissues
beyond an age when the animal would be likely to contribute
genetically to future generations (Kirkwood 2005; Medawar
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1952; Williams 1957). Similarly, there is little selective
pressure to limit cancer in old animals who are substantially
beyond their reproductive years (DeGregori 2011). For
example, while mice can live two to four years in the lab
and tend to develop cancer in their second and third years, it is
rare to find a mouse greater than one year old in the wild
(Kirkwood 2005). Most wild mice will be dead from other
causes such as cold, hunger, disease, or predators well before
the age when cancer would be a likely cause of their demise.
Thus, evolution has favored a “breed early, breed often” strategy
for mice. Investment in better tissue maintenance or cancer
prevention well after one year would have required allocation of
precious energy early in life, when this energy would be better
spent on survival and reproduction during youth.
The situation in humans is more complex, as even our
hunter–gatherer ancestors may have had a reasonable
chance of living past 50 once they survived to adulthood
(Kaplan et al. 2000). It is notable however that survival into
older adulthood was probably much lower prior to the
Upper Paleolithic (10,000–40,000 years ago; Caspari and
Lee 2004). Regardless, the chances of older humans
contributing to the gene pool of future generations should
have declined with age, as an earlier demise due to disease,
starvation, predators, or other causes became more likely
(and for females, the chances of successfully raising
offspring became less likely). Thus, evolutionary invest-
ments in tumor suppression may have waned in older age.
So while George Bernard Shaw remarked that “Youth is
wasted on the young,” “youthfulness” (and fitness; see Box 1
for definitions of italicized words) is maintained precisely
where it is needed: during the period when reproductive
success is most likely. Moreover, some processes which are
important for organismal fitness in youth may actually
contribute to tissue decline and increased cancer in old age,
a concept known as antagonistic pleiotropy (Campisi 2005).
Thus, evolution has in effect weighed the costs and benefits
of somatic tissue maintenance and tumor suppression,
favoring a strategy that maximizes reproductive success.
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Evolved Tumor Suppression
Just as organisms evolve, tissue (somatic) cells can also evolve
within an animal. Somatic cell evolution, which can lead to
tissue-disrupting tumors and cancer, is clearly detrimental to
the fitness of the organism (with the exception of cell evolution
within the immune system). The reason that cancer is so rare
during youth is that multi-cellular organisms, particularly long-
lived and large ones, have evolved potent tumor-suppressive
mechanisms (but see Box 2 for evolutionary explanations for
childhood cancers). Indeed, the evolution of multi-cellularity
required it. We can imagine that the first multi-cellular
organisms, no matter how simple, would not have been able
to evolve significant organization or complexity without
mechanisms to avoid rogue cell growth. But how could a
group of cells representing a recently evolved multi-cellular
organism have prevented one of their own from acquiring a
short-term advantage (i.e. rogue cells, out-proliferating their
peers), even if it was to the eventual detriment of the
organism? Successful multi-cellular organisms evolved mech-
anisms to limit these nonconformist outgrowths. We will refer
to these tumor-suppressive mechanisms as either intrinsic (how
cells avoid becoming tumor cells) or integral (cancer avoidance
at the level of tissues and the whole organism).
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Intrinsic Tumor Suppression
Cells of multi-cellular organisms have evolved mecha-
nisms to maintain appropriate numbers of cells within
tissues. Both cell division and cell survival are
regulated by various “social” cues including circulating
factors and contact with other cells (Hanahan and
Weinberg 2011). Importantly, there are often mechanisms
to penalize disobedient cells. For example, dividing
outside of the appropriate structure, such as a well-
ordered duct, can lead to cell suicide (a program that is
activated within the cell that leads to cell death) (Hipfner
and Cohen 2004). These mechanisms are essential for the
proper development and function of complex tissues and
organs. Animals have also evolved cell suicide and cell
senescence responses to inappropriate signals, such as
those engendered by cancer-causing (oncogenic) muta-
tions (Lowe et al. 2004). Similar cell death and
senescence responses are initiated following cellular
damage, particularly damage to DNA. These intrinsic
mechanisms contribute to tumor suppression (Lowe et al.
2004) by limiting the chances that damaged, and possibly
oncogenic, cells are propagated. In addition, oncogenic
mutations are avoided in cells by effective DNA repair
(Hoeijmakers 2009), which even unicellular organisms
use to maintain the integrity of their genetic material.
Another intrinsic tumor-suppressive mechanism is
mediated by telomeres, which cap chromosome ends to
help maintain the integrity of the DNA code (Sharpless
and DePinho 2004; Chan and Blackburn 2004). Single-
cell organisms as well as germ cells of animals maintain
telomeres continuously as a means to ensure correct
propagation of their genetic code. But somatic cells in
adult tissues do not maintain telomeres continuously, and
these structures are reduced in length with age, until a
critically short length stimulates cell death or senescence
(which may contribute to tissue decline with aging).
Larger animals appear to particularly favor this mecha-
nism to limit telomere maintenance during aging, which
by restricting each somatic cell's lifespan is thought to
limit cancer (which requires immortal cells; Gorbunova
and Seluanov 2009). Together, all of these mechanisms
function within cells to limit their ability to disobey tissue
rules, thus reducing the risk of cancer.
Integral Tumor Suppression
Compared to other animals (and with notable exceptions),
vertebrates have longer lives and bigger bodies, providing a
bigger pool of cells over longer time periods in which an
oncogenic mutation may arise. Consequently, vertebrates
should have increased requirements for suppression of rogue
cell growth. While enhancements in the intrinsic tumor-
suppressive mechanisms discussed above may have contrib-
uted to improved tumor suppression in the large and long-
lived, additional mechanisms operating at the tissue and
animal levels clearly function in vertebrates (and to varying
extent in other animals) to limit cancer development. These
integral tumor-suppressive mechanisms include immunity,
tissue organization, and the fitness of stem cell pools.
Vertebrates have evolved effective immune systems, and
even invertebrates possess simple immune systems (Robert
2010). In particular, vertebrates have evolved antigen-
specific immunity, with lymphocytes that are tailored to
recognize and respond to specific foreign or abnormal
proteins (“antigens,” whether these antigens are part of
viruses, bacteria, or cancer cells). In addition to eliminating
pathogens and limiting infections, these systems can target
precancerous and cancerous cells for destruction, thus
contributing to tumor suppression (Robert 2010). Indeed,
patients with defective cellular immunity have increased
cancer risk (Dunn et al. 2004).
The evolution of animals and their tissues, organs, and
systems has been constrained by the requirement to avoid
tumors (Cairns 1975; reviewed in DeGregori 2011). These
constraints on how tissues develop and are organized
should be particularly severe for animals with larger bodies
and longer lives, which require tissue maintenance and
renewal throughout life. Tissue organization contributes to
the “peer pressure” exerted on malignant cells, whereby
normal tissue structure can suppress rogue cell expansion
(Bissell and Hines 2011). Also contributing to tumor
suppression, tissues in vertebrates are often maintained by
a hierarchy of cells, with a small number of stem cells
serving as the source of the much more numerous
specialized cells that actually carry out the functions of
the tissue (Weissman 2000). Stem cells are thought to often
represent the targets for cancer initiation (Reya et al. 2001).
These cells are maintained throughout life, increasing the
opportunities for mutation accumulation. Importantly, hier-
archical tissue organization, with a few stem cells at the top
of the hierarchy, would reduce the pool of cells most
susceptible to oncogenic mutations. Stem cells in tissues
also appear to be positioned in protective locations (their
niche). For example, blood stem cells are localized in the
bone marrow, and gut stem cells are positioned distant from
the nasty contents of the large intestine (Cairns 1975; Reya
et al. 2001; Gatenby et al. 2010), which should reduce
exposure to carcinogens. Most cell proliferation is delegated
to non-stem cells (which are derived from stem cells) in the
hierarchy, and these cells are generally short-lived. Indeed,
for the intestines, these non-stem cells (even if they acquire
an oncogenic mutation) are destined for a one-way trip out
the anus (hence mutations get “flushed”) (Frank and Nowak
2004; Pepper et al. 2007). Thus, vertebrates have evolved
effective strategies to minimize cancer rates, despite a
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dizzying number of cell divisions required daily to maintain
some organs like the blood, skin, and intestines throughout
life. For example, each human produces around 1011 (one
trillion) blood cells each day (Gordon et al. 2002). There were
probably other possible approaches to the development and
maintenance of vertebrate organs, but each successful solution
needed to be compatible with sufficiently low rates of cancer.
The fact that cancer has exerted developmental con-
straints during evolution provides another reason that
cancer biologists need to understand evolutionary biology,
and all biologists need to learn about cancer: Just as one
cannot really understand cancer without understanding how
evolution has limited it, one cannot fully understand the
evolution of form and function in multi-cellular organisms
without considering how the requirement for tumor
suppression has constrained it. So cancer biology courses
should not just be for medical students, and evolutionary
biology should be required for all life science disciplines,
including medicine. Teaching students about cancer from an
evolutionary perspective would not only enhance the students'
understanding of cancer, but would provide highly relevant
examples for why evolutionary biology is so important.
Students should learn that fighting cancer requires an
understanding of its evolutionary origins and how it adapts
to current therapies to the detriment of cancer patients.
Integral Tumor Suppression by Maintaining Tissue
Fitness
Cancer progression occurs by a process of somatic cell
evolution whereby a cell clone acquires a number of genetic
changes over time and proliferates to generate a highly
complex cancer (DeGregori 2011; Merlo et al. 2006; Bagby
and Fleischman 2011). This evolutionary process is driven
by two major forces:
1) genetic variation in somatic cell populations, which
facilitates the acquisition of mutations in oncogenes
and tumor suppressor genes;
2) selection for cells that harbor mutations increasing their
cellular fitness relative to competing cells.
Certain cells in a tissue with potential to proliferate, like
stem cells, are in competition with each other for nutrients,
growth factors, survival factors, and spatial locations (Baker
2011; Fleenor et al. 2010), which together constitute their
niche. How fit the competing cells are, as well as the state of
the niche, can in a large part determine whether an acquired
oncogenic mutation leads to expansion of the cell clone.
Thus, consideration of cancer development as an evolution-
ary process within an individual provides a different
perspective relative to the more widely accepted focus on
oncogenic mutations as the primary drivers of cancer.
We have proposed that long-lived multi-cellular organisms
have evolved highly fit stem cell populations, not only as a
means of efficiently maintaining tissues but also because a
highly fit cell population should oppose somatic cell evolution
(DeGregori 2011). Like animal populations well adapted to
their environments, cell populations with high fitness should
be resistant to change: The chance that a mutation improves
fitness will be much less when there is little room for
improvement. Highly effective competition in a young,
healthy stem cell population should serve to maintain the
status quo, preventing somatic cell evolution. In other words,
non-conformist cells are suppressed via competition by their
fit neighbors (Fig. 1, top), just as a healthy lawn can limit
weed growth.
But when general cellular fitness is reduced, such as with
aging or following damaging carcinogen exposure, certain
oncogenic mutations can be adaptive (restoring fitness;
Fig. 1, bottom). An oncogenic mutation could be adaptive
by circumventing or fixing problems caused by the damage
and may be adaptive in a cell under one set of conditions
but not another. For example, if a carcinogen causes
widespread cell death in a tissue, there will be increased
selection for oncogenic mutations that promote cell survival.
Damage to the niche, which also occurs with aging or
carcinogen exposure, can also increase selection for adaptive
mutations. In some ways, these concepts are analogous to the
acquisition of antibiotic resistance in gut flora: Antibiotic
treatment will select for mutant bacteria resistant to the
antibiotic and will also destroy competing bacteria and
substantially alter the niche.
So just as evolution of species is driven by mutation
and selection, cancer evolution is also driven by both
oncogenic mutations and alterations in selective pres-
sures, both of which can result from aging and
carcinogenic exposures. For example, smoking not only
exposes your lungs to DNA-damaging chemicals that
can cause oncogenic mutations (Hecht 2002) but also
should dramatically alter selective pressures within the
lung: Normal lung stem cells are highly damaged
(reducing their fitness), and the environment that these
cells are in (their niche) is highly perturbed (remember the
black lungs in a jar that you were shown to keep you from
smoking?). Damage to the landscape of the lung also leads
to compensatory proliferation to fill empty niches
(Takahashi et al. 2010), providing increased opportunities
for cancers to develop. Massive destruction of the
landscape, such as after the gigantic meteor hit off the
Gulf of Mexico at the Cretaceous–Tertiary (K–T) Bound-
ary ∼65 million years ago, can lead to new speciation as
organisms adapt to the new environment (Raup 1986). The
same probably applies within an individual, although
somatic cell evolution within an individual is inherently
dangerous, as it can lead to cancer.
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So what lessons can we take from these evolutionary
considerations of cancer? For starters, we cannot simply
focus on the cancer but need to consider its environment
within the body. We need to learn how to attack the cancer
and at the same time support the immune system, boost
normal cell fitness, and restore a more normal niche. For
cancer prevention, maintaining fit tissues by doing all of the
things we already know are good for us (eat well, don't
smoke, exercise, etc.), should help prevent cancer by
maintaining fit cells within a tissue, making it harder for a
rogue early cancer cell to outcompete normal cells and
expand. The following sections will continue our
discussion of cancer as an evolutionary process: How
do cells that acquire oncogenic mutations eventually
evolve into complex and invasive cancers? How can an
evolutionary viewpoint help explain carcinogen-induced
cancers? How can an evolutionary understanding of
cancer improve therapeutic approaches to combat cancer?
Evolutionary Perspectives on Multistage Carcinogenesis
and Metastasis
The currently accepted oncogenesis model, initially
described by Nowell (1976), states that tumors originate
from benign growths with minor genetic alterations. Over
time, these growths accumulate mutations and advance to
more aggressive cancers. In some cases, cancerous cells
can disseminate from the original tumor and invade
various organs and tissues, a process known as metastasis.
Hanahan and Weinberg (2011) have outlined the key
biological properties, or hallmarks, of cancer cells, which
include: (a) having self-sufficiency in growth signals, (b)
loss of sensitivity to anti-growth signals, (c) loss of
sensitivity to programmed cell suicide, (d) immortality
(cells can divide forever), (e) altered metabolic properties,
(f) higher mutation rates, (g) ability to attract blood
vessels, and (h) the capacity to invade tissues and become
metastatic. So how are normal cells, which are part of a
strict tissue organization with cellular social cues, trans-
formed into cellular sociopaths who disregard tissue order
and ignore cellular dialog?
Hallmarks of cancer are acquired via mutational changes
that provide a potential tumor cell with a fitness advantage
relative to normal cells within the same niche, thereby
promoting the expansion of the tumor cell clone. As discussed
above, whether these mutations confer a cellular fitness
advantage should be dependent on the state of the neighbor-
hood (competing cells and the state of the niche). Moreover,





Fig. 1 Oncogenic mutations
will rarely be advantageous
within a population of healthy
well-adapted stem cells residing
in a healthy niche, leading to
loss of the oncogenic clone over
time (top). But following aging
or damage-induced reductions in
stem pool fitness, together with
damage or degradation of the
niche, oncogenic events that
improve fitness should provide
selective advantages, leading to
expansion of the oncogenic
clone over time (bottom).
Cellular competition is denoted
with arrows, with darker arrows
indicating greater competition
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growing tumor alters its local environment, and thus the
parameters that dictate selection for particular mutations
change as the cancer develops (Gatenby and Gillies
2008).
Alterations in the local tissue environment progressively
create barriers to continued cancer evolution (Gatenby and
Gillies 2008), and these barriers are typically effective,
preventing further tumor development. Such barriers
include oxygen and nutrient limitations that require the
acquisition of mutations that promote metabolic changes
and/or increase the blood supply. Thus, the hallmarks of
cancer described above are the result of cancer evolution as
it overcomes selection barriers. These barriers could
account for the frequent observation of benign and typically
innocuous tumors in tissues in the elderly (Greaves 2007):
Most cell clones that start down the path of cancer
(fortunately) never progress to the point of clinical
relevance (necessitating removal or treatment).
Metastasis is itself a multistage process whereby cancer
cells from the original tissue location (the primary tumor)
are able to colonize other sites including distant organs
(Hanahan and Weinberg 2011). Malignant cells commence
this process by local invasion of the organ occupied by the
primary tumor. Next, cancer cells escape into either the
lymphatic or blood vessel circulation, where they must be
able to survive until they can reach a tissue and establish a
metastatic tumor growth. Continued growth of metastases
in distant organs eventually leads to failure of the colonized
organ(s), and is the primary cause of death for cancer
patients. Fortunately, each of these steps, from escape out
of the primary tumor, survival in the blood/lymph stream,
colonization of a distant tissue, to successful growth of the
metastatic tumor in a foreign site, represents a substantial
hurdle for the tumor cells. The vast majority of tumor cells
will not overcome these hurdles. Only the rare cancer
cells possess the appropriate combination of genetic
changes and luck (from the cancer's perspective) to
initiate a metastatic tumor. Thus, each of these hurdles
confers a powerful selective pressure, with selection for
particular tumor cell genotypes.
We can envision metastasis in evolutionary terms as an
aggressive invasive species (metastatic cancer cells), which
migrates into a new environment (organ or tissue),
disregarding niche organization and hierarchy. Over time,
the invading species takes over this environment and either
drives away (out-competes) or kills the native species
(leading to organ failure). But why would migratory ability
of cancer cells be advantageous in the first place, given that
non-migratory cells in the primary tumor might have the
advantage that resources could be spent on cell division
rather than migration (Bernards and Weinberg 2002)?
Indeed, in a homogeneous tumor, migration reduces cancer
cell fitness (Chen et al. 2011).
But malignant tumors, particularly ones with metastatic
potential, are not homogeneous and instead present diverse
environments for cancer cells. Using ecological principles
from migratory animal populations, modeling studies have
shown how migratory ability, by increasing the ability of a
cancer clone to sample different environments with variable
resources in the primary tumor, can provide a selective
advantage within the primary tumor by allowing the cancer
cell clone to experience more favorable environments
(Chen et al. 2011). Thus, understanding cancer from an
evolutionary and ecological perspective can shed light on
its most deadly manifestation: metastasis.
Carcinogens as Promoters of Somatic Cell Evolution
Carcinogen is a scary word. Carcinogens are agents that
contribute to cancer development, and often attributing
carcinogenic potential to a substance can be quite contro-
versial, since whether an agent can cause cancer can be
dependent on the test or criteria used (Loeb and Harris
2008). For some carcinogens like cigarette smoking, the
case is closed, given incontrovertible epidemiological and
laboratory evidence. As discussed above, smoking
contributes to lung cancer evolution by both increasing
mutation frequency as well as by altering the tissue
environment to increase selection for adaptive oncogenic
mutations. However, given the traditional focus of
cancer biology on mutations, and not selection, the
most frequently used tests for carcinogens (such as the
Ames test; Mortelmans and Zeiger 2000) only determine
whether a substance increases mutations, ignoring potential
impacts on selection. The only reasonable method to
determine the latter requires animal models, which are much
more expensive and require humane considerations, and
limiting the numbers of animals used entails application of
unnatural doses of the suspected carcinogen. But if we
consider that cancer is impeded by a healthy normal tissue
environment, then the ability of a suspected carcinogen to
perturb tissue structure and health could be used as a surrogate
for a “cancer-favoring context” in order to justify more
expensive cancer studies.
Carcinogens engender two of the major forces for
evolutionary change: increased genetic diversity in a
population and alterations of selective pressures. Both
natural and synthetic compounds can initiate cancer (Loeb
and Harris 2008). Among natural carcinogens, a prime
example is the potent microbial toxin Aflatoxin B1,
produced by the fungus Aspergillus flavus. Chronic
exposure to this toxin, mostly found in stored grains and
nuts, has been shown to highly predispose to liver cancer
(Farazi and DePinho 2006). Even bacteria are now accepted
as cancer-causing agents, with Helicobacter pylori (causative
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of gastric ulcers) increasing stomach cancer risk (Piazuelo et
al. 2010). The resulting inflammation may contribute to
stomach cancer risk both by increasing DNA-damaging
agents in the tissue as well as by creating an abnormal tissue
environment favoring malignant cancer evolution. We are
also exposed to intrinsic carcinogens, such as oxidative
products of metabolism, which can contribute to DNA
mutations (together with the intrinsic error rate of our cell's
DNA replication and repair machinery) (Liou and Storz
2010). Thus, even if we avoided any contact with man-made
chemicals, we would still be exposed to carcinogens.
Over the last hundred and fifty years, there have been
colossal strides in different areas of science and society
which have been translated into massive technological
advances. As a by-product of these changes, Homo sapiens
currently encounter a plethora of new chemical and
physical agents that were not present in nature throughout
our long evolutionary history. For example, early humans
(and our non-human ancestors) did not encounter any of the
synthetic organic molecules we are currently exposed to
such as vinyl chloride, dioxins, or benzene (all shown to
cause cancers; Loeb and Harris 2008). Consequently,
humans did not evolve effective means of protecting their
bodies from these novel insults. Even though our enzymatic
detoxification systems can still recognize functional groups
within these molecules, they are not completely efficient in
guarding our bodies from the onslaught of foreign
molecular insults. This is especially evident in industrial
workers who are exposed to new compounds, resulting in
higher incidences of diseases like cancers. Modern humans
are also exposed to amounts of ionizing radiation (like X
and gamma rays), whether resulting from nuclear fission or
medical use, which far exceed natural levels experienced by
our ancestors (Fleenor et al. 2010; Little 2000). Another
prime example is modern cancer chemotherapy, where
patients are inundated with cytotoxic therapies that not only
kill cancer cells but impinge on the health of normal tissues
(even leading to new cancers that emerge years later; Allan
and Travis 2005). Thus, we must consider that we did not
evolve to deal with these carcinogenic insults, which not
only increase mutation rates but also can alter selective
pressures (thus promoting somatic cell evolution).
Viewing Cancer Therapies Through an Evolutionary
Lens
At this point, hopefully you can now envision cancer as a
disease heavily dependent of evolutionary principles and
ecological relationships (Merlo et al. 2006). An advanced
cancer is a microcosm of cells with ample genetic
variability where each cancer cell clone can be considered
a competing (or sometimes cooperating) sub-species. This
genetic variability can be attributed to the often higher
mutation rates, multiple selective hurdles, variable micro-
environments, and increased numbers of cell generations
that characterize cancers. Cancers consist of from a billion
to a thousand billion (1012) cells, resulting from hundreds
to thousands of cell generations (Siegmund et al. 2009),
which is on the scale of the number of generations spanning
the entire evolutionary history of H. sapiens. And just as for
animal populations, this great genetic variability in the
cancer population provides ample opportunities for adapta-
tion to change and the evolution of diverse types (Marusyk
and Polyak 2010). Selective pressures, whether exerted by
lack of nutrients, radiation exposure, or chemotherapy, can
select for clones that are most adaptive to these conditions
and can create an evolutionary bottleneck whereby the
selected cells populate the majority of the tumor. We can
also consider the hosts' immune system as a predatory
selection force which may counteract tumor growth but also
select for clones that can “tame” the immune system (and
even subvert immune cells for its own nefarious means;
Dunn et al. 2004).
Since the origins of oncology, systemic cytotoxic
chemotherapy has been the primary strategy for patients
with advanced cancers (Mukherjee 2010). While we find a
plethora of chemotherapy drugs in use in the clinic, their
common fundamental role is to either kill cancer cells or
stop their growth potential. With some exceptions like
childhood leukemia, this approach has rarely led to cures
for disseminated cancers. Although it is understood that
cancer is a complex and dynamic disease, it is currently
treated according to fixed, linear protocols. Patients are
treated with the highest tolerable chemotherapy dose, with
the goal of killing the maximum amount of cancer cells.
But tumors are highly adaptive and dynamic systems that
can evolve strategies to overcome chemotherapy. Although
cytotoxic treatment can initially cause a major reduction of
the tumor size, this also creates powerful pressure that will
frequently select for clones that have intrinsic resistance to
the regimen. This evolutionary ability of the tumor cells
thus results in regimen failure and regrowth of the cancer,
populated by resistant cells (Fig. 2, top).
Mathematical modeling, with model testing in mice,
suggests that chemotherapy-sensitive cells in the tumor are
often more fit and actually suppress the growth of the less
fit chemotherapy resistant clones (Gatenby et al. 2009).
Thus, there is probably a fitness cost to chemo-resistance.
These researchers envision a mode of cancer therapy which
adapts to the predominating species in the tumor: Treat and
debulk the tumor with chemotherapy but still maintain a
chemo-sensitive population to oppose the growth of chemo-
resistant clones. Thus, the treatment would cause the tumor
size to follow a sinusoid growth curve (a smooth repetitive
oscillating pattern), with periods of growth and shrinkage,
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but not a complete eradication of the tumor mass (Fig. 2,
bottom). Interestingly, Gatenby and collaborators show that
this approach, at least in a mouse tumor model, provides
better survival than the current standard protocols, notably
with substantially lower doses of chemo drugs (Gatenby et
al. 2009). Thus, although this approach has not been tested
clinically, we may be able to harness the inherent
competitive nature of cancer cells for patient benefit.
Another approach to cancer treatment that recognizes the
adaptive nature of cancer populations is via targeted therapies.
Cancer research over the last 50 years has revealed extensive
insight into the proteins and enzymes that drive cancer
initiation and maintenance, leading to the creation of targeted
drugs that inhibit the oncogenic driver (the mutated oncogene
that the cancer depends on; Hanahan and Weinberg 2011).
Thus, these smart drugs target a small number of proteins in
the cell, which contrasts with the scorched-earth approach
using DNA-damaging chemotherapies. While the targeted
approach has produced some notable successes, such as for
chronic myelogenous leukemia, the development of resis-
tance is a substantial problem, particularly for more
advanced (and hence complex) cancers (Daley 2003; Bunn
2007). Given that we currently possess a growing list of
targeted drugs against specific oncogenes, current
approaches would initiate treatment against oncogene A,
and once resistance and relapse occur due to a mutation-
activating oncogene B, the patient would be treated with a
drug that would selectively inhibit oncogene B. But if we
instead consider evolutionary and ecological principles, and
we can recognize that it would be easier to eliminate cancer
cells with oncogene B before these cells are selected for and
dominate the cancer, we can predict that developing
combination therapies up front that target both the driving
oncogene and anticipated escape mechanisms will be more
effective. But to uncover these escape mechanisms (in
essence, before they happen), we have to understand the
evolutionary trajectories of cancers under different contexts.
If we can anticipate how the cancer in patient 1 with driver
oncogenic mutation A will evolve in response to a drug
targeting oncogene A, which could be different from the
cancer in patient 2 with oncogenic mutation X, then we can
better treat each patient. But as we've learned, we must also
consider the entire environment for the cancer (the patient),
and therapeutic strategies will need to be tailored dependent
on the genotype of the patient and many other parameters
(age, exposures, etc.).
Finally, using evolutionary principles, can we treat
cancer with the goal of avoiding metastatic events? As
mentioned before, a tumor is a complex, dynamic system




















Fig. 2 Top panel. Current chemotherapy regimens initially cause a
major reduction of the tumor size, which mostly kills chemo-sensitive
cells. This creates a powerful selective pressure that will inevitably
benefit clones (shown in dark gray) that have intrinsic resistance to the
treatment. Thus, chemo-resistant clones, now unhindered by compe-
tition from chemo-sensitive clones, can repopulate the landscape
and eventually emigrate to other tissues. Bottom panel. Proposed
adaptive cancer therapy, in which the tumor is partially debulked
with a mild chemotherapy regimen but where a portion of the
chemo-sensitive population is allowed to survive and oppose the
growth of chemo-resistant clones (dark gray cells). Thus, this type of
treatment would cause the tumor size to follow a sinusoid growth
curve with periods of growth and shrinkage. This approach should
control tumor burden but without the goal of complete eradication of
the disease
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motility should actually be disadvantageous in a homoge-
neous environment, increased mobility can be advanta-
geous under variably harsh conditions (Chen et al. 2011).
Given the dense, cell-compacted nature of tumors, acidic
and low oxygen conditions inevitably ensue, which
interestingly have been mechanistically shown to promote
the evolution of clones which are prone to emigrate from
the tumor. In other words, the same environment selects for
clones that can depart from the main tumor and establish
new colonies in greener pastures. If, for example, we could
re-oxygenate tumors and prevent low oxygen conditions,
we could theoretically prevent the rise of clones with a
more motile phenotype and decrease the possibility of a
successful metastatic event. This approach has been tested
in animal models (Mazzone et al. 2009), with encouraging
results. Thus, understanding cancers from an ecological and
evolutionary perspective can lead to innovative approaches
to control and target this deadly disease.
Conclusions
Understanding cancer, both at the tissue and animal levels,
demands an evolutionary perspective. The evolution of multi-
cellular animals, particularly those like us with large bodies
and long lives, necessitated the acquisition of potent tumor-
suppressive mechanisms, which operate at levels of individual
cells, tissue organization, and the whole body to limit cancers.
Cancer itself follows an evolutionary trajectory, with acquisi-
tion of mutations that allow the cancer cells to adapt and
succeed, from the initial tiny tumor to a metastatic monster. We
have discussed how carcinogenic contexts from chemicals, to
radiation, to aging, can promote cancer evolution both by
increasing mutation frequency and by promoting selection for
adaptive mutations. And like animal populations, cancers
respond to insults with selection for the clones that are most fit
under that context, such as during chemotherapy. While this
view may seem depressing from a therapeutic standpoint, by
understanding cancer from an evolutionary and ecological
perspective, we should be able to design more rational
therapeutic approaches that manipulate cancer's evolutionary
trajectories for patient benefit.
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